Whalesbook
Profitability Pressures Mount
UTI AMC's operational results for the fourth quarter of fiscal year 2026 showed mixed performance. Revenue from operations stood at INR 3.7 billion, up 4% from the previous year but down 5% from the prior quarter. Management fee earnings also dropped to 38.6 basis points, from 42.4 basis points a year ago and 40.1 basis points last quarter. Total operating expenses rose 10% year-over-year, leading to an 11% shortfall in Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA), which totaled INR 1.5 billion. The EBITDA margin fell to 39.3%, compared to 42.6% a year ago and 45.6% last quarter. These quarterly figures contrasted with the full fiscal year 2026, which saw revenue grow 7% to INR 15.4 billion. Despite these challenges, UTI AMC shares trade between ₹1,035-₹1,065, well below average analyst 12-month price targets of ₹1,202 to ₹1,258.
Valuation Gaps and Industry Shifts
UTI AMC trades at a Price-to-Earnings (P/E) ratio of 21.27x to 24.50x, a significant discount compared to larger peers. HDFC Asset Management Company trades at a P/E of 32.7x to 41.74x, and ICICI Prudential AMC at 49.3x to 50.13x. This lower valuation may reflect market concerns about UTI AMC's performance or industry-wide pressures. The Indian asset management sector is changing structurally. While Systematic Investment Plan (SIP) contributions are strong, reaching over INR 32,000 crore monthly by March 2026, investors are favoring lower-cost passive funds. This trend, with passive Assets Under Management (AUM) hitting INR 50 lakh crore by April 2026, directly impacts fee earnings. New SEBI expense ratio rules, effective April 1, 2026, also add to margin pressure by lowering investor fees and thus AMC profit margins. UTI AMC is responding by investing in digital tools, expanding sales teams, and aiming to grow its overall AUM.
Earnings Drop, Regulatory Hurdles
UTI AMC's recent quarterly results show significant earnings volatility. The company reported a consolidated net loss of INR 66.7 crore for the fourth quarter of fiscal year 2026, a sharp reversal from a profit in the prior year. Full-year fiscal 2026 net profit fell 45% year-on-year to INR 404 crore. This earnings sensitivity to market conditions and costs is a key issue. Lower management fee earnings and EBITDA margins, along with an 11% earnings shortfall and higher expenses, show the difficulty of staying profitable as lower-yield passive products gain favor. UTI AMC is debt-free and offers a dividend yield, but its sales growth has been low at 11.8% over the past five years. The new regulatory framework on expense ratios, effective April 2026, is expected to further limit profits, possibly pressuring margins more than the market expects.
Analysts Expect Growth Despite Challenges
Despite mixed financial results and industry pressures, most analysts remain positive on UTI AMC. Motilal Oswal reiterated its 'BUY' rating with a price target of INR 1,270, based on 24 times estimated fiscal year 2028 core earnings per share. Other analysts share this view, with consensus 12-month price targets indicating potential upside of 20-36% from current prices. These targets are based on expected AUM growth from UTI AMC's investments in technology and distribution. Analysts believe the company can navigate the changing industry. However, achieving these targets will require UTI AMC to offset lower earnings and manage costs effectively amid growing regulatory scrutiny and competition from passive funds.